Rebound Hypersecretion after Inhibition of Gastric Acid Secretion

Qvigstad, Gunnar; Waldum, Helge L.

doi:10.1111/j.1742-7843.2004.pto940502.x

Cited by 27 publications

(32 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased gastric acid secretion is well described after stopping the long-term use of histamine H 2 -receptor antagonists[18,65], however its occurrence after the prolonged use of PPIs is controversial[18,66•]. Some studies provide evidence it occurs in 60–90% of patients after long-term PPI usage[18,65].…”

Section: Advances In Other Nonzes Gastric Acid Hypersecretory Smentioning

confidence: 99%

“…Some studies provide evidence it occurs in 60–90% of patients after long-term PPI usage[18,65]. Evidence has been provided that the mechanism of the rebound hypersecretion post use of PPIs was, at least in part, mediated by the hypergastrinemia that occurred as result of the marked inhibition of the acid secretion by the PPI[18,65].…”

Section: Advances In Other Nonzes Gastric Acid Hypersecretory Smentioning

confidence: 99%

See 1 more Smart Citation

Gastric acid hypersecretory states: Recent insights and advances

Osefo¹,

Ito²,

Jensen

2009

Curr Gastroenterol Rep

View full text Add to dashboard Cite

Gastric acid hypersecretory states are a group of disorders characterized by basal hypersecretion of gastric acid and historically include a number of disorders associated with hypergastrinemia, hyperhistaminemia and of unknown etiology. Although gastric acid secretion is infrequently measured, it is important to recognize the role of gastric hypersecretion in the symptomatology of these disorders because they share a number of features of symptom pathogenesis and in treatment. In this article recent important articles reporting insights into their diagnosis, pathogenesis and treatment are reviewed. Particular attention is paid to Zollinger-Ellison syndrome, because it has the most extreme acid hypersecretion of this group of disorders and because of the large number of recent articles dealing with various aspects of the diagnosis, molecular pathogenesis or treatment of the gastrinoma itself or the acid hypersecretion. Two new hypersecretory disorders including rebound acid hypersecretion after the use of PPIs and acid hypersecretion with cysteamine treatment in children with cytinosis are also reviewed.

show abstract

Section: Advances In Other Nonzes Gastric Acid Hypersecretory Smentioning

confidence: 99%

Section: Advances In Other Nonzes Gastric Acid Hypersecretory Smentioning

confidence: 99%

Gastric acid hypersecretory states: Recent insights and advances

Osefo¹,

Ito²,

Jensen

2009

Curr Gastroenterol Rep

View full text Add to dashboard Cite

show abstract

“…We believe this decrease in periampullary cancer risk as cDDD levels increase beyond 180 days is partly attributed to mechanism of PPI tolerance. Studies on H2RAs (another medication commonly used for GERD and PUD) have found that tolerance of the drug decreases after previous drug treatments, especially intravenous medication 39, 40. It is possible that patients on long‐term PPI use encounter similar tolerance problems with PPI just as patients experience with H2RAs.…”

Section: Discussionmentioning

confidence: 99%

Proton pump inhibitors and risk of periampullary cancers—A nested case–control study

Chien

Huang

Shao

et al. 2015

Intl Journal of Cancer

View full text Add to dashboard Cite

Considerable attention has been focused on long‐term use of proton pump inhibitor (PPI) medications in relation to increased risk of cancer via stimulation of DNA‐damaged cells. The aim of this study is to examine the dose‐dependent effect of PPI on periampullary cancers in a national population‐based cohort. A nested case–control analysis was constructed based on Taiwan's National Health Insurance Research Database and the Taiwan Cancer Registry between the years 2000 and 2010. Cases involving patients diagnosed with periampullary cancers were selected and controls were matched to cases according to age, sex and observational period. A “PPI user” was defined as any patient receiving more than 28 cumulative defined daily doses as measured by prescription drug claims. Conditional logistic regression analysis was conducted to calculate odds ratios (ORs) and 95% confidence intervals (CIs) according to the level of PPI exposure. A total of 7,681 cases and 76,762 matched controls were included with a mean follow‐up period of 6.6 years (SD: 2.0). The odds of PPI exposure in patients with periampullary cancers were higher than that of control patients with an adjusted OR of 1.35 (95% CIs: 1.16–1.57). Our results also showed that PPI exposure was slightly linked to periampullary cancers in dose‐dependent manner. A similar association was observed in patients who solely took PPI but no eradication therapy for Helicobacter pylori infection. Long‐term PPI use was associated with an increased risk of periampullary cancers in the current population‐based study. Physicians must weigh potential risks of long‐term maintenance against therapeutic benefit.

show abstract

“…Increased gastric acid secretion is well described after stopping the long-term use of H 2 RA [52,53], but its occurrence after the prolonged use of PPIs is controversial. It seems that there is no strong evidence for a clinically relevant increased acid output after PPI therapy is stopped [51,52,53]. Three uncontrolled trials nevertheless suggested an increase in acid secretory capacity in H. pylori- negative subjects after 8 weeks of treatment [54,55].…”

Section: What Do We Know About Unmet Needs?mentioning

confidence: 99%

“…Rebound is clinically important because it seems that it contributes to the recurrence of GERD [50]. There are four mechanisms to explain rebound: upregulation of H 2 receptors, hypergastrinemia-stimulating histamine release by enterochromaffin-like cells, increase of parietal cell mass and upregulation of H + ,K + -ATPase activity [51]. Increased gastric acid secretion is well described after stopping the long-term use of H 2 RA [52,53], but its occurrence after the prolonged use of PPIs is controversial.…”

Section: What Do We Know About Unmet Needs?mentioning

confidence: 99%

Pharmaceutical Principles of Acid Inhibitors: Unmet Needs

Krznarić

Kelečić²,

Rustemović³

et al. 2011

Dig Dis

View full text Add to dashboard Cite

Despite the well-established benefits of currently approved delayed-release proton pump inhibitors (PPIs) in the treatment of acid-related diseases, the unmet needs are still present and although often frustrating, they challenge clinicians. The unmet needs relate to the lack of complete control of acid secretion with oral PPI administration in the management of patients with gastroesophageal symptoms. These substantial groups of patients, who do not respond completely to standard doses of PPIs, are nonresponders, and their lack of response should be considered as PPI failure. Several mechanisms could explain PPI failure: differences in pharmacokinetics, PPI formulation, dosing time and diet, noncompliance, transient lower esophageal sphincter relaxations, esophageal hypersensitivity, and nocturnal acid breakthrough. To increase the quality of life of these patients and avoid multiple medical consultations and unnecessary investigations, we have to go one step forward and use combined therapy or look towards new treatments beyond acid suppression.

show abstract

Rebound Hypersecretion after Inhibition of Gastric Acid Secretion

Cited by 27 publications

References 68 publications

Gastric acid hypersecretory states: Recent insights and advances

Gastric acid hypersecretory states: Recent insights and advances

Proton pump inhibitors and risk of periampullary cancers—A nested case–control study

Pharmaceutical Principles of Acid Inhibitors: Unmet Needs

Contact Info

Product

Resources

About